The γδ T cells belong to a subgroup of T cells known as non-conventional T cells due to their limited T cell receptor (TCR) repertoire and ability to recognize non-peptide antigens. They play a crucial role in combating infections and tumors. Vγ9Vδ2 T cells are typically activated by molecules containing diphosphate groups, collectively known as phosphoantigens (pAgs), through a non-canonical mechanism which involves the intracellular domain of butyrofilin (BTN)3A1 protein. However, no FDA-approved drugs have yet been shown to activate them, and the underlying cellular mechanisms remain unknown. In this study, we combined high-throughput virtual screening of an FDA-approved drug database with in vitro cellular assays to identify potential γδ T cells activators. Our findings demonstrate that Nitazoxanide (NTZ) and Tinidazole induce moderate elicited a statistically significant increase in interferon (IFN)-γ production of Vγ9Vδ2 T cells by their probably interaction with the pAg binding site of BTN3A1. Additionally, NTZ induces expression of CD107a, but only at the highest concentrations tested and promotes the upregulation of HLA-DR in total PBMCs and CD14+ monocytes. Blocking BTN3A with a specific antibody led to a marked reduction in all NTZ-induced activations. This work identifies NTZ as a previously unrecognized activator of γδ T cells, highlighting its immunomodulatory potential beyond its known clinical uses. These findings broaden our understanding of γδ T cells pharmacology and suggest new opportunities for drug repurposing and the design of novel chemical scaffolds. Further mechanistic studies will be essential to fully define how NTZ engages the BTN3A–γδ T cells axis.
COVID-19 vaccines remain essential for pandemic control, but antibody responses wane, and viral variants emerge. Affordable platforms enabling local manufacturing are important for equitable vaccine access in low- and middle-income countries (LMICs). The locally developed and manufactured NDV-vectored AVX/COVID-12 “Patria” vaccine may help address this need. We conducted an exploratory analysis of antigen-specific cellular immunity in 17 healthy SARS-CoV-2-naïve volunteers from a previously reported phase I safety and immunogenicity cohort (NCT04871737). Eight participants received intramuscular (IM) and nine received intranasal (IN) vaccination. Peripheral blood collected through 90 days was stimulated in vitro with recombinant Wuhan-Spike protein and analyzed using activation-induced marker (AIM) assays, intracellular cytokine staining, and high-dimensional flow cytometry. AIM+ CD4+ T-cell frequencies peaked around day 28 at 0.45 (1.13)% after IM and 0.18 (0.6)% after IN vaccination, while AIM+ CD8+ T-cell responses remained lower, reaching 0.09 (0.22)% and 0.03 (0.33)%, respectively, median (IQR). Cytokine-producing T-cell responses showed no consistent route-related differences. High-dimensional analysis identified multiple activation-associated phenotypes in CD3+ and CD3− compartments, across both vaccination routes, with distinct temporal dynamics. These exploratory findings show systemic Spike-responsive T-cell activation in this cohort after both routes and provide a refined characterization of vaccine-induced cellular immunity, warranting further investigation of IN administration.